Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.

Ther Adv Urol · 2018 · PMC6295778 · PMID 30574205

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

Nevertheless, median OS was not reached in the apalutamide group and was 39.0 months in the placebo group, showing a favorable hazard ratio which did not reach statistical significance (HR: 0.70; 95% CI: 0.47–1.04; p = 0.07).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.